{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:57:05Z","timestamp":1781672225075,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists, have demonstrated substantial efficacy in weight management. However, real-world treatment experience, tolerability, and treatment continuation remain important challenges, and the determinants of patient satisfaction are not fully understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional online survey was conducted between January and February 2025 across international incretin therapy communities. The study included 411 adults with obesity (BMI \u226530 kg\/m\u00b2) or overweight with comorbidities (BMI 27\u201329.9 kg\/m\u00b2) receiving semaglutide or tirzepatide for \u22653 months. Treatment satisfaction was assessed using the validated Treatment-Related Impact Measure\u2013Weight (TRIM-Weight). Patient-reported changes in appetite regulation, mood, physical activity, sexual health, self-image, and social experiences were evaluated using 5-point Likert scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants had a median age of 39 years (IQR 33\u201347), 71.8% were female, and the median treatment duration was 10 months (IQR 7\u201313), with 34.3% reporting treatment for \u226512 months. In univariate analyses, higher treatment satisfaction was associated with improvements in appetite regulation, mood, physical activity, sexual satisfaction, self-image, and positive social feedback, as well as fewer limitations due to side effects (all p &amp;lt; 0.05). In fully adjusted multivariable models, fewer limitations due to side effects (\u03b2 = 1.41; 95% CI 0.25\u20132.88), increased satiety (\u03b2 = 0.68; 95% CI 0.10\u20131.29), improved mood (\u03b2 = 0.69; 95% CI 0.19\u20131.28), and higher physical activity (\u03b2 = 0.58; 95% CI 0.10\u20131.17) remained independently associated with higher TRIM-Weight scores. Greater BMI reduction was associated with higher treatment satisfaction in the individually adjusted model, but this association was attenuated and no longer statistically significant in the fully adjusted model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment satisfaction was more strongly associated with tolerability, satiety, mood, and physical activity than with BMI change or medication type. These findings support incorporating patient-reported outcomes when evaluating incretin-based therapies in real-world obesity care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1864209","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:48:24Z","timestamp":1781671704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study"],"prefix":"10.3389","volume":"17","author":[{"given":"Ali","family":"Kapan","sequence":"first","affiliation":[{"name":"Center for Public Health, Department of Social and Preventive Medicine, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othmar","family":"Moser","sequence":"additional","affiliation":[{"name":"Exercise Physiology, Training and Training Therapy Research Group, Institute of Human Movement Science, Sport and Health, University of Graz","place":["Graz, Austria"]},{"name":"Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz","place":["Graz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Felsinger","sequence":"additional","affiliation":[{"name":"Center for Public Health, Department of Social and Preventive Medicine, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Waldhoer","sequence":"additional","affiliation":[{"name":"Center for Public Health, Department of Epidemiology, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13098-023-01198-4","article-title":"Efficacy and safety of tirzepatide, dual GLP-1\/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Zhou","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/med.22070","article-title":"Incretin\u2010based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future","volume":"45","author":"Psaltis","year":"2025","journal-title":"Med Res Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz072","article-title":"Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials","volume":"105","author":"DeSouza","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100836","article-title":"Long-term effect of sleeve gastrectomy vs Roux-en-Y gastric bypass in people living with severe obesity: a phase III multicentre randomised controlled trial (SleeveBypass)","volume":"38","author":"Biter","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.23332","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/bs14060480","article-title":"Patient adherence to a real-world digital, asynchronous weight loss program in Australia that combines behavioural and GLP-1 RA therapy: a mixed methods study","volume":"14","author":"Talay","year":"2024","journal-title":"Behav Sci (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33393\/dti.2021.2342","article-title":"The role of patient preferences in adherence to treatment in chronic disease: a narrative review","volume":"15","author":"Losi","year":"2021","journal-title":"Drug Target Insights"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13816","article-title":"Improved treatment satisfaction in patients with type 2 diabetes treated with once\u2010weekly semaglutide in the SUSTAIN trials","volume":"21","author":"Jendle","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16222","article-title":"Survey among adult users of semaglutide for weight loss in Denmark: user characteristics, treatment expectations and experienced effects","author":"S\u00f8rensen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2022.105667","article-title":"Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial","volume":"137","author":"van Ruiten","year":"2022","journal-title":"Psychoneuroendocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01620-8","article-title":"Tirzepatide improved health-related quality of life compared with insulin lispro in basal insulin-treated adults with type 2 diabetes and inadequate glycaemic control: a randomised controlled phase 3b trial (SURPASS-6)","volume":"15","author":"Boye","year":"2024","journal-title":"Diabetes Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6.3.e34","article-title":"Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES)","volume":"6","author":"Eysenbach","year":"2004","journal-title":"J Med Internet Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/gox.0000000000000665","article-title":"The BODY-Q: a patient-reported outcome instrument for weight loss and body contouring treatments","volume":"4","author":"Klassen","year":"2016","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2001.13","article-title":"Development of a brief measure to assess quality of life in obesity","volume":"9","author":"Kolotkin","year":"2001","journal-title":"Obes Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-8-19","article-title":"Development and validation of the treatment related impact measure of weight (TRIM-Weight)","volume":"8","author":"Brod","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1467-789x.2005.00170.x","article-title":"Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain","volume":"6","author":"Elfhag","year":"2005","journal-title":"Obes Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.17.2133","article-title":"Obese patients' perceptions of treatment outcomes and the factors that influence them","volume":"161","author":"Foster","year":"2001","journal-title":"Arch Intern Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.293","article-title":"Social support for healthy behaviors: scale psychometrics and prediction of weight loss among women in a behavioral program","volume":"20","author":"Kiernan","year":"2012","journal-title":"Obes (Silver Spring)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20814","article-title":"Influence of family, friend and coworker social support and social undermining on weight gain prevention among adults","volume":"22","author":"Wang","year":"2014","journal-title":"Obes (Silver Spring)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjad211","article-title":"Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google Trends analysis","volume":"44","author":"Han","year":"2023","journal-title":"Aesthet Surg J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2023.04.057","article-title":"Ozempic face: a new challenge for facial plastic surgeons","volume":"81","author":"Tay","year":"2023","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2024.07.051","article-title":"The rise of \"Ozempic Face\": analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists","volume":"96","author":"Mansour","year":"2024","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/aco.0000000000000131","article-title":"The Helsinki declaration on patient safety in anaesthesiology","volume":"27","author":"Mellin-Olsen","year":"2010","journal-title":"Eur J Anaesthesiology| EJA"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1864209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:48:29Z","timestamp":1781671709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1864209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":35,"alternative-id":["10.3389\/fendo.2026.1864209"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1864209","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1864209"}}